WHAT IS CLAIMED IS:

Claim 1. A method of treating a cancer comprising administering a PD-1 x LAG-3 bispecific molecule to a subject in need thereof, wherein said method comprises administering said PD-1 x LAG-3 bispecific molecule to said subject at a flat dose of from about 120 mg to about 800 mg.

Claim 2. The method of claim 1, wherein said cancer is characterized by the expression of a Tumor Antigen (TA), and wherein said method further comprising administering to said subject a Tumor Antigen (TA) Binding Molecule (TA-Binding Molecule).

Claim 3. A method of treating a cancer in a subject, wherein said cancer is characterized by the expression of a TA, said method comprising administering a TA-Binding Molecule to said subject and:

(a) a bispecific (PD-1 x LAG-3 bispecific molecule); or

(b) a molecule that immunospecifically binds PD-1 (PD-1-Binding Molecule) in combination with a molecule that immunospecifically binds LAG-3 (LAG-3-Binding Molecule); or

(c) a bispecific molecule that immunospecifically binds both PD-L1 and LAG-3 (PD-L1 x LAG-3 bispecific molecule); or

(d) a molecule that immunospecifically binds PD-L1 (PD-L1-Binding Molecule) in combination with a LAG-3-Binding Molecule.

Claim 4. The method of any one of claims 2-3, wherein said TA-Binding Molecule comprises an ADCC-Enhanced Fc Domain.

Claim 5. The method of any one of claims 2-4, wherein:

(a) each molecule is in a separate composition; or

(b) each molecule is in the same composition; or

(c) said PD-1-Binding Molecule and said LAG-3-Binding Molecule are in the same composition, and said TA-binding molecule is in a separate composition; or

(d) said PD-L1-Binding Molecule and said LAG-3-Binding Molecule are in the same composition, and said TA-binding molecule is in a separate composition.

Claim 6. The method of any one of claims 2-5, wherein said TA-Binding Molecule is an antibody.

Claim 7. The method of any one of claims 2-6, wherein said PD-1-Binding Molecule is an antibody, said PD-L1-Binding Molecule is an antibody, and said LAG-3-Binding Molecule is an antibody.

Claim 8. The method of any one of claims 3-6, wherein said method comprises administering said TA-Binding Molecule and said PD-1 x LAG-3 bispecific molecule.

Claim 9. The method of any one of claims 4-8, wherein said ADCC-Enhanced Fc Domain comprises:

(A) an engineered glycoform; and/or

(B) an amino acid substitution relative to a wild-type Fc Region.

Claim 10. The method of claim 9, wherein said ADCC-Enhanced Fc Domain comprises:

(A) an engineered glycoform that is a complex N-glycoside-linked sugar chain that does not contain fucose, and/or that comprises a bisecting O-GlcNAc; and/or

(B) comprises an amino acid substitution is selected from the group consisting of:

(a) one substitution selected from the group consisting of:
F243L, R292P, Y300L, V305I, I332E, and P396L;

(b) two substitutions selected from the group consisting of:

(1) F243L and P396L;

(2) F243L and R292P;

(3) R292P and V305I; and

(4) S239D and I332E;

(c) three substitutions selected from the group consisting of:

(1) F243L, R292P and Y300L;

(2) F243L, R292P and V305I;

(3) F243L, R292P and P396L; and

(4) R292P, V305I and P396L;

(d) four substitutions selected from the group consisting of:

(1) F243L, R292P, Y300L and P396L; and

(2) F243L, R292P, V305I and P396L; or

(e) five substitutions selected from the group consisting of:

(1) F243L, R292P, Y300L, V305I and P396L; and

(2) L235V, F243L, R292P, Y300L and P396L,

wherein the numbering is that of the EU index as in Kabat.

Claim 11. The method of any one of claims 9-10, wherein said ADCC-Enhanced Fc Domain comprises the amino acid substitutions: L235V, F243L, R292P, Y300L and P396L, wherein the numbering is that of the EU index as in Kabat.

Claim 12. The method of any one of claims 2-11, wherein:

(A) said TA is selected from **Table 6A** or **Table 6B**; and/or

(B) said TA-Binding Molecule comprises the VL and VH Domains of an antibody selected from **Table 7**.

Claim 13. The method of any one of claims 3-7, or 9-12, wherein:

(A) said PD-1-Binding Molecule is an antibody that comprises:

(a) a PD-1 VL Domain that comprises the amino acid sequence of **SEQ ID NO:35**, and a PD-1 VH Domain that comprises the amino acid sequence of **SEQ ID NO:39**;

(b) a VH and VL Domain of an anti-PD-1 antibody selected from **Table 1**; or

(c) a light chain and a heavy chain of an anti-PD-1 antibody selected from **Table 1**;

(B) said PD-L1-Binding Molecule is an antibody that comprises:

(a) a PD-L1 VL Domain that comprises the amino acid sequence of **SEQ ID NO:43**, and a PD-L1 VH Domain that comprises the amino acid sequence of **SEQ ID NO:47**;

(b) a VH and VL Domain of an anti-PD-L1 antibody selected from **Table 2**; or

(c) a light chain and a heavy chain of an anti-PD-L1 antibody selected from **Table 2**; and

(C) said LAG-3-Binding Molecule is an antibody that comprises:

(a) a LAG-3 VL Domain that comprises the amino acid sequence of **SEQ ID NO:51**, and a LAG-3 VH Domain that comprises the amino acid sequence of **SEQ ID NO:55**;

(b) a VH and VL Domain of an anti-LAG-3 antibody selected from **Table 3**; or

(c) a light chain and heavy chain of an anti-LAG-3 antibody selected from **Table 3**.

Claim 14. The method of any one of claims 1-6, 8, or 9-12, wherein said PD-1 x LAG-3 bispecific molecule comprises:

(a) a PD-1 VL Domain that comprises the amino acid sequence of **SEQ ID NO:35**, and a PD-1 VH Domain that comprises the amino acid sequence of **SEQ ID NO:39**, or a VH and VL Domain of an anti-PD-1 antibody selected from **Table 1**; and/or

(b) a LAG-3 VL Domain that comprises the amino acid sequence of **SEQ ID NO:51**, and a LAG-3 VH Domain that comprises the amino acid sequence of **SEQ ID NO:55**, or a VH and VL Doman of an anti-LAG-3 antibody selected from **Table 3**; or

(c) a bispecific Antibody-Based Molecule selected from **Tables 4-5**.

Claim 15. The method of any one of claims 1-6, 8, 9-12 or 14, wherein said PD-1 x LAG-3 bispecific molecule comprises:

(a) two of said PD-1-Binding Domains; and

(b) two of said LAG-3-Binding Domains.

Claim 16. The method of any one of claims 1-6, 8, 9-12, or 14-15, wherein said PD-1 x LAG-3 bispecific molecule comprises the PD-1 VL Domain of **SEQ ID NO:35**, the PD-1 VH Domain of **SEQ ID NO:39**, the LAG-3 VL Domain of **SEQ ID NO:51**, and the LAG-3 VH Domain of **SEQ ID NO:55**.

Claim 17. The method of any one of claims 1-6, 8, 9-12, or 14-16, wherein said PD-1 x LAG-3 bispecific molecule or said PD-L1 x LAG-3 bispecific molecule comprises an Fc Region and a Hinge Domain.

Claim 18. The method of claim 17, wherein said Fc Region and said Hinge Domain are both of the IgG4 isotype, and wherein said Hinge Domain comprises a stabilizing mutation.

Claim 19. The method of any one of claims 17-18, wherein said Fc Region is a variant Fc Region that comprises:

(a) one or more amino acid modifications that reduces the affinity of the variant Fc Region for an FcγR; and/or

(b) one or more amino acid modifications that enhances the serum half-life of the variant Fc Region.

Claim 20. The method of claim 19, wherein said:

(a) modifications that reduce the affinity of the variant Fc Region for an FcγR comprise the substitution of L234A; L235A; or L234A and L235A; and

(b) modifications that enhances the serum half-life of the variant Fc Region comprise the substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y, S254T and T256E; or K288D and H435K,

wherein said numbering is that of the EU index as in Kabat.

Claim 21. The method of any one of claims 1-6, 9-12, or 14-20, wherein said PD-1 x LAG-3 bispecific molecule comprises two polypeptide chains of **SEQ ID NO:59** and two polypeptide chains of **SEQ ID NO::60**.

Claim 22. The method of any one of claims 1-6, 9-12, or 14-21, wherein said PD-1 x LAG-3 bispecific molecule or said PD-L1 x LAG-3 bispecific molecule is administered at a flat dose of about 300 mg.

Claim 23. The method of any one of claims 1-6, 9-12, or 14-21, wherein said PD-1 x LAG-3 bispecific molecule or said PD-L1 x LAG-3 bispecific molecule is administered at a flat dose of about 600 mg.

Claim 24. The method of any one of claims 1-6, 9-12, or 14-23, wherein said flat dose is administered once about every 2 weeks.

Claim 25. The method of any one of claims 1-6, 9-12, or 14-23, wherein said flat dose is administered once about every 3 weeks.

Claim 26. The method of any one of claims 1-6, 9-12, 14-21, 23, or 24, wherein said PD-1 x LAG-3 bispecific molecule or said PD-L1 x LAG-3 bispecific molecule is administered at a flat dose of about 600 mg once about every 2 weeks.

Claim 27. The method of any one of claims 1-6, 9-12, 14-21, 23, or 25, wherein said PD-1 x LAG-3 bispecific molecule or said PD-L1 x LAG-3 bispecific molecule is administered at a flat dose of about 600 mg once about every 3 weeks.

Claim 28. The method of any one of claims 1-6, 9-12, or 14-27, wherein said PD-1 x LAG-3 bispecific molecule or said PD-L1 x LAG-3 bispecific molecule is administered by intravenous (IV) infusion.

Claim 29. The method of any one of claims 1-28, wherein said cancer is selected from the group consisting of: adrenal gland cancer, AIDS-associated cancer, alveolar soft part sarcoma, anal cancer (including squamous cell carcinoma of the anal canal (SCAC)), bladder cancer, bone cancer, brain and spinal cord cancer, breast cancer (including, $HER2^+$ breast cancer or Triple-Negative Breast Cancer (TNBC)), carotid body tumor, cervical cancer (including, HPV-related cervical cancer), chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, desmoplastic small round cell tumor, ependymoma, endometrial cancer (including, unselected endometrial cancer, MSI-high endometrial cancer, dMMR endometrial cancer, and/or POLE exonuclease domain mutation positive endometrial cancer), Ewing's sarcoma, extraskeletal myxoid chondrosarcoma, gallbladder or bile duct cancer (including, cholangiocarcinoma bile duct cancer), gastric cancer, gastroesophageal junction (GEJ) cancer, gestational trophoblastic disease, germ cell tumor, glioblastoma, head and neck cancer (including, squamous cell carcinoma of head and neck (SCCHN)), a hematological malignancy, a hepatocellular carcinoma, islet cell tumor, Kaposi's Sarcoma, kidney cancer,

leukemia (including, acute myeloid leukemia), liposarcoma/malignant lipomatous tumor, liver cancer (including, hepatocellular carcinoma liver cancer (HCC)), lymphoma (including, diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma (NHL)), lung cancer (including, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC)), medulloblastoma, melanoma (including, uveal melanoma), meningioma, Merkel cell carcinoma, mesothelioma (including, mesothelial pharyngeal cancer), multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancer, papillary thyroid carcinoma, parathyroid tumor, pediatric cancer, peripheral nerve sheath tumor, pharyngeal cancer, pheochromocytoma, pituitary tumor, prostate cancer (including, metastatic castration resistant prostate cancer (mCRPC)), posterious uveal melanoma, renal metastatic cancer, rhabdoid tumor, rhabdomyosarcoma, sarcoma, skin cancer, a small round blue cell tumor of childhood (including neuroblastoma and rhabdomyosarcoma), soft-tissue sarcoma, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid cancer, and uterine cancer.

Claim 30. The method of claim 29, wherein said cancer is selected from the group consisting of: anal cancer, breast cancer, bile duct cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, GEJ cancer, head and neck cancer, liver cancer, lung cancer, lymphoma, melanoma, ovarian cancer and prostate cancer.

Claim 31. The method of any one of claims 28 or 29, wherein said cancer is selected from the group consisting of: $HER2^+$ breast cancer, TNBC, cholangiocarcinoma bile duct cancer, HPV-related cervical cancer, SCCHN, HCC, SCLC or NSCLC, NHL, prostate cancer, gastric cancer and GEJ cancer.

Claim 32. The method of any one of claims 2-31, wherein said TA-Binding Molecule is a HER2-Binding Molecule comprising a HER2-Binding Domain comprising a Light Chain Variable Domain (VL_{HER2}) and a Heavy Chain Variable Domain (VH_{HER2}), wherein:

(A) said Light Chain Variable Domain (VL_{HER2}) comprises the Light Chain Variable Domain of margetuximab that comprises the CDR_L1, CDR_L2 and CDR_L3 of **SEQ ID NO:61**, and said Heavy Chain Variable Domain (VH_{HER2}) comprises the Heavy Chain Variable Domain of margetuximab that comprises the CDR_H1, CDR_H2 and CDR_H3 of **SEQ ID NO:66**;

(B) said Light Chain Variable Domain (VL_{HER2}) comprises the CDR_L1, CDR_L2 and CDR_L3 of trastuzumab and said Heavy Chain Variable Domain (VH_{HER2}) comprises the CDR_H1, CDR_H2 and CDR_H3 of trastuzumab;

(C) said Light Chain Variable Domain (VL_{HER2}) comprises the CDR_L1, CDR_L2 and CDR_L3 of pertuzumab and said Heavy Chain Variable Domain (VH_{HER2}) comprises the CDR_H1, CDR_H2 and CDR_H3 of pertuzumab; or

(D) said Light Chain Variable Domain (VL_{HER2}) comprises the CDR_L1, CDR_L2 and CDR_L3 of hHER2 MAB-1 and said Heavy Chain Variable Domain (VH_{HER2}) comprises the CDR_H1, CDR_H2 and CDR_H3 of hHER2 MAB-1.

Claim 33. The method of any one of claims 2-32, wherein said HER2-Binding Molecule is an anti-HER2 antibody.

Claim 34. The method of claim 33, wherein said anti-HER2 antibody is margetuximab, and said method comprises administering margetuximab at a dosage of about 6 mg/kg to about 18 mg/kg once about every 3 weeks.

Claim 35. The method of any one of claims 32-34, wherein said method further comprises administered a chemotherapeutic agent.

Claim 36. The method of any one of claims 2-35, wherein said cancer is a HER2 expressing cancer.

Claim 37. The method of claim 36, wherein said HER2 expressing cancer is selected from the group consisting of: breast cancer, metastatic breast cancer, bladder, gastric cancer, GEJ cancer, ovarian cancer, pancreatic cancer, and stomach cancer.

Claim 38. The method of any one of claims 2-31, wherein said TA-Binding Molecule is a B7-H3-Binding Molecule comprising a B7-H3-Binding Domain comprising a Light Chain Variable Domain (VL) and a Heavy Chain Variable Domain (VH), wherein:
said VL comprises the CDR_L1, CDR_L2 and CDR_L3 of **SEQ ID NO:71**, and said VH the CDR_H1, CDR_H2 and CDR_H3 of **SEQ ID NO:76**.

Claim 39. The method of any one of claims 2-31 or 38, wherein said TA-Binding Molecule is enoblituzumab and said method comprises administering enoblituzumab at a dosage of about 6 mg/kg to about 18 mg/kg once about every 3 weeks.

Claim 40. The method of any one of claims 2-31 or 38-39, wherein said cancer is a B7-H3 expressing cancer.

Claim 41. The method of claim 40, wherein said B7-H3 expressing cancer is selected from the group consisting of: anal cancer, SCAC, a breast cancer, TNBC, a head and neck cancer, SCCHN, lung cancer, NSCLC, melanoma, uveal melanoma, prostate cancer, and mCRPC.

Claim 42. The method of any one of claims 2-41, wherein said TA-binding molecule is administered by intravenous (IV) infusion.

Claim 43. The method of any one of claims 1-42, wherein cells expressing LAG-3 are present in a biopsy of said cancer prior to said treatment.

Claim 44. The method of any of claims 1-43, wherein cells expressing PD-1 are present in a biopsy of said cancer prior to said treatment.

Claim 45. The method of any one of claims 2-44, wherein PD-L1 expression on the surface of cells of said cancer, prior to said treatment, is less than 1% as determined using a Combined Positive Score (CPS) or a Tumor Proportion Score (TPS).